University College London – Great Ormond Street Institute of Child Health
This is an opportunity for a Grade 7 postdoctoral research scientist funded by a Cystic Fibrosis Trust Strategic Research Centre grant to join a team of molecular geneticists and clinicians on an exciting project to develop gene editing therapies for lung disease of cystic fibrosis, a rare, recessively-inherited, respiratory disease caused by mutations is the CF gene.
Gene editing will be performed by CRISPR/Cas9, a powerful new technique with the potential to correct specific gene mutations at the chromosomal level, for long-term corrective therapy. CRISPR/Cas9 technologies for gene editing have developed rapidly in the past two years but optimizing the delivery of nucleic acids for gene editing with therapeutic applications for CF remains a challenge.
This post is based in the Experimental and Personalised Medicines Section of the Genetics & Genomic Medicine Programme at ICH. Our group has long-standing expertise in developing nanoparticle formulations for lung delivery of genetic therapies for respiratory diseases and combines that with the clinical expertise in CF at Great Ormond Street Hospital.
Applicants should have a PhD in a relevant subject with expertise in cell and molecular biology. They must have excellent cell culture skills and experience in the molecular analysis of gene expression. Effective communication skills, written and oral, will be essential. An interest in CF, nanoparticles and the challenges of gene delivery to the respiratory epithelium would be an advantage.
UCL vacancy reference: 1708036
Applicants should apply online. To access further details about the position and how to apply please click on the ‘Apply’ button below.
If you have any queries regarding the vacancy or the application process, please contact email@example.com
Latest time for the submission of applications: Jan 31st 2018 – 23.59.
Interview Date: TBC
Any offer of employment will be subject to a Disclosure and Barring Service (DBS) check.